)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Passage Bio
Passage Bio (PASG) investor relations material
Passage Bio Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary10 Aug, 2026
Executive summary
Entered into a merger agreement with Remix Therapeutics, expected to close in Q4 2026, with significant changes to business focus and management post-merger.
Wound down gene therapy programs, terminated key collaborations, and initiated a major workforce reduction (75%).
Substantial doubt exists about ability to continue as a going concern without additional funding or completion of the merger.
Financial highlights
Net loss for Q2 2026 was $7.8 million, improved from $9.4 million in Q2 2025; net loss for the first half of 2026 was $15.4 million, down from $24.8 million year-over-year.
Cash and cash equivalents were $24.2 million as of June 30, 2026, compared to $46.3 million at year-end 2025.
Research and development expenses decreased to $3.3 million in Q2 2026 from $5.8 million in Q2 2025; general and administrative expenses increased to $6.9 million from $4.5 million.
Recorded a $1.9 million net gain on lease termination in Q2 2026.
Outlook and guidance
Completion of the merger with Remix is critical for ongoing operations; failure to close may result in inability to continue as a going concern.
No guidance provided for future revenue due to wind-down of legacy programs and pending merger.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Passage Bio
- Merger creates a leading RNA-focused biotech with REM-422 poised for ACC and AML impact.PASG
Investor presentation - Merger forms a biotech leader in RNA-targeted therapies with $100M in new funding.PASGM&A announcement
- All proposals passed, including annual advisory votes on executive compensation.PASGAGM 2026
- Q1 2026 net loss narrowed, but cash shortfall drives strategic review and major cost cuts.PASGQ1 2026
- PBFT02 gene therapy demonstrated durable biomarker and clinical benefits in FTD-GRN.PASGCorporate presentation
- PBFT02 gene therapy shows durable biomarker response and early disease-modifying potential in FTD-GRN.PASGCorporate presentation
- Virtual annual meeting to vote on directors, auditor, and executive pay proposals.PASGProxy filing
- Shareholders will vote on directors, auditor, and executive pay, with strong governance and ESG focus.PASGProxy filing
- Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning.PASGTD Cowen 46th Annual Health Care Conference
Next Passage Bio earnings date
Q3 202610 Nov, 2026
Passage Bio
Next Passage Bio earnings date
Q3 202610 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Passage Bio Inc. is a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders. The company utilizes a proprietary gene therapy platform in collaboration with the University of Pennsylvania’s Gene Therapy Program to deliver adeno-associated virus (AAV)-based therapeutics directly to the CNS. Passage Bio’s pipeline includes treatments targeting conditions such as frontotemporal dementia, Krabbe disease, and other inherited neurodegenerative and neurodevelopmental disorders. The company is headquartered in Philadelphia, Pennsylvania, and its shares are listed on the NASDAQ.